October 1st, 2020 | 13:25 CEST
BioNTech, NEL ASA, BYD: Which shares will rise afterward?
In international comparison, BioNTech is one of the leading pharmaceutical companies in the fight against corona. The research team is receiving substantial funding and support from investors and government agencies for the development of a vaccine against Covid-19. NEL ASA is one of the pioneers in the hydrogen sector and is involved in the development of plant infrastructure for multiple projects. BYD is a company from China that trades as a future competitor of Tesla in investor circles. All companies have proven to be successful. Their share prices have reflected this success having multiplied drastically this year. This has resulted in several billion Euro market valuations. Once a vaccine against Covid-19 becomes available, one industry will benefit particularly and it offers an excellent entry scenario for investors.
time to read: 2 minutes | Author: Mario Hose
ISIN: NL0000235190 , US0970231058 , CA2446331035
Table of contents:
Author
Mario Hose
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Tag cloud
Shares cloud
Total deceleration of everyday life
The spread of Covid-19 has brought many areas of everyday life to a standstill. During the particularly severe restrictions from March to May 2020, the streets were empty and air traffic significantly less. During this time, most people only bought their essentials. People felt vulnerable and restricted their consumption in fear of the unknown - or were forced to out of lack of choice.
Vaccinations are being prepared
Due to the efforts being made by biotechnology companies such as BioNTech, CureVac, and Sanofi to bring a vaccine against Covid-19 to market maturity, it is expected that vaccinations can be started in the first quarter of 2021 at the latest. As BioNTech alone is aiming for a production volume of up to one billion vaccine doses per year, it can be assumed that by 2022 at the latest all people - who so desire - will have been vaccinated.
Vaccination record as a voluntary mandatory document
Once a vaccine against COVID-19 is available, politics and the economy can begin returning to normal. Those who are vaccinated are likely to gain more freedom than those who reject its use due to the obvious risk with non-vaccine takers. When entering a function or boarding a plane, people may in the future not only be asked for their identity card but also their vaccination record. Judging by past events this year, nothing can be ruled out and everything is possible.
Trading houses position themselves for a price increase
The experts from Citigroup and Goldman Sachs have announced their assessment of a winner of the Post Covid-19 period. This is an area that has been pushed aside and avoided by the capital market in recent months. The time has now come for industry experts and investors to position themselves for what is to come.
Be greedy when others are afraid
The analysts of the two financial institutions assume that the overcapacity of crude oil will be used up in 2021 and that the price per barrel will rise again to USD 60.00 or higher. The shares of oil companies are currently still at rock bottom and are attracting little attention. Now is a good time to consider buying shares of producers that are positioned in a legally secure space and prioritise environmental protection. It is important that the company was profitable and had low production costs before the Covid-19 pandemic.
Positive analyst opinion
The Canadian oil producer Saturn Oil & Gas is one such company. During 2019, the company was profitable and was able to report attractive growth rates in revenues. CEO John Jeffrey has already announced that the company will be looking at acquisitions to benefit from the current situation. In recent months, the situation has been correspondingly quiet. Investors in Saturn Oil & Gas may therefore benefit twice over. At CAD 0.10, the currently unheeded share is still trading well below the price of CAD 0.30 two years ago. In the period before Covid-19, the analysts of GBC Research gave a target price of 0.31 CAD in their buy recommendation - this would result in a highly attractive return.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
